Q-omics provides the consensus-scored NUDT4P2 profile across patient tissues and cancer cell-line models. NUDT4P2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, NUDT4P2 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, NUDT4P2 RNA expression shows 6,031 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight READ, KIRC, and ESCA as cancer lineages where NUDT4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT4P2 survival associations across molecular data types. NUDT4P2 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT4P2 RNA expression–survival associations across cancer types. High NUDT4P2 expression shows unfavorable associations in KICH and UVM, but favorable associations in READ, SKCM, COAD and OV. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify READ as the clearest survival context for NUDT4P2 RNA expression.
This table summarizes NUDT4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NUDT4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT4P2 shows lower tumor expression in KIRC and KICH and higher tumor expression in PRAD. The KIRC box plot shows higher NUDT4P2 RNA expression in normal versus tumor tissue (log2 FC = −0.049, t-test p < 0.001).
This table shows molecular features associated with NUDT4P2 in patient tissues and cancer cell lines. In patient samples, NUDT4P2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
